Review the latest information on the efficacy and safety of fixed-dose LAMA/LABA combinations in treatment of patients with COPD, as presented at a recent meeting in San Francisco. Ask our experts your questions related to COPD and find answers to questions from the meeting.

2017 ATS COPD: To Use or Not Use ICS? The Shifting Paradigm in COPD Treatment

Review the latest information on the use of ICS in patients with COPD in these clinical scenarios as presented by Drs. Gary T. Ferguson, James F. Donohue, and Nicola A. Hanania at a recent meeting in Washington, DC.

Download [pptx » 8MB]



Fixed Dose LAMA/LABA Inhalers in COPD: What the Trials Tell Us

2016 ATS COPD: Fixed Dose LAMA/LABA Inhalers in COPD: What the Trials Tell Us

These slides are from a symposium held in San Francisco on May 17, 2016. Through an interactive, case-based format, Dr. Richard Casaburi, Dr. Gary Ferguson, and Dr. David Mannino present an overview of the efficacy and safety of current and emerging fixed dose LAMA/LABA combination inhalers for patients with COPD.

Click here to download the COPD Foundation's provider and patient resource sheet

Download [pptx » 3MB]


Long-acting bronchodilators are the cornerstone of maintenance therapy for patients with chronic obstructive pulmonary disease (COPD). A variety of long-acting muscarinic antagonists (LAMA) and long-acting β2-agonists (LABAs) are available for the management of COPD. An increasing number of fixed-dose LAMA/LABA combinations have been developed and approved; these combinations have the potential to provide synergistic effects through different mechanisms of action, maximize bronchodilation, and simplify COPD treatment regimens. Authored by Richard Casaburi, MD, Gary Ferguson, MD, and David Mannino, MD, this supplement provides a review of the safety and efficacy of current and emerging inhaled fixed-dose LAMA/LABA combinations for patients with COPD.


FAQ is an opportunity for you to have your COPD clinical questions addressed by expert faculty. Your questions will be answered by email within 2 weeks.



Does the FLAME data put indacaterol/glycopyrrolate as a superior LABA/LAMA in the ex US scenario based on existing evidence to date?

These video-based roundtable discussions highlight key COPD updates provided at a May 2017 meeting on pulmonary disease. Expert faculty reflect on new information on COPD and discuss the impact it has for patients.


Access other Therapeutic Areas: